- Feature Paper
- Article
PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
- Dolores Isla,
- Alfredo Sánchez,
- Joaquín Casal,
- Manuel Cobo,
- Margarita Majem,
- Noemi Reguart,
- Jon Zugazagoitia and
- Reyes Bernabé
Introduction: There are currently three first-line immunotherapy options used as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand 1 (PD-L1) expression (≥50%). This manuscript aims to evaluate th...